Large-cap Health Care company Novo Nordisk A/S has moved 8.6% so far today on a volume of 7,040,435, compared to its average of 4,663,781. In contrast, the S&P 500 index moved 1.0%.
Novo Nordisk A/S trades 0.4% away from its average analyst target price of $135.0 per share. The 7 analysts following the stock have set target prices ranging from $123.16 to $140.18, and on average have given Novo Nordisk A/S a rating of buy.
If you are considering an investment in NVO, you'll want to know the following:
-
Novo Nordisk A/S has moved 75.7% over the last year, and the S&P 500 logged a change of 30.3%
-
Based on its trailing earnings per share of 2.71, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 50.0 while the S&P 500 average is 15.97
-
NVO has a forward P/E ratio of 34.2 based on its forward 12 month price to earnings (EPS) of $3.96 per share
-
The company has a price to earnings growth (PEG) ratio of 93.93 — a number near or below 1 signifying that Novo Nordisk A/S is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 5.67 compared to its sector average of 4.08
-
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
-
Based in Bagsvaerd, the company has 63,370 full time employees and a market cap of $604.87 Billion. Novo Nordisk A/S currently returns an annual dividend yield of 7.5%.
